Pilot study on the effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial

Abstract

N-3 polyunsaturated fatty acids (LCPUFA-ω3), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) might have beneficial effects on lean mass and fat mass synthesis. To investigate the effect of LCPUFA-ω3 supplementation on body composition changes in children with acute lymphoblastic leukemia (ALL) at remission and three months (3mo) after supplementation. This randomized controlled trial enrolled 72 children (3-13y) with newly diagnosed ALL (placebo group [500mg sunflower oil]: 36 patients; LCPUFA-ω3 group [225mg DHA, 45mg EPA]: 36 patients). LCPUFA-ω3 was administered at 0.100g/kg of body weight/day for 3mo. Both groups were provided with an oral milkshake supplement. Body composition was measured at diagnosis, remission, and 3 months after supplementation by dual-energy X-ray absorptiometry (DXA). Red blood cell fatty acid analyses were performed with gas chromatography. Student's t test compared the percentage changes in body weight, total body fat percentage (TBFP), and lean body mass (LBM) between the groups. The Mann-Whitney U test was used to compare the groups, and the Friedman range test and Wilcoxon signed rank test were used for intratreatment comparisons. Spearman correlation coefficients were calculated for LBM and erythrocyte LCPUFA-ω3 content. LBM decreased significantly in both groups. This loss was greater in the placebo group than in the LCPUFA-ω3 group at remission (p=0.044) and at 3 months of supplementation (p=0.039). There were significant and progressive increases in DHA and EPA concentrations in the LCPUFA-ω3 group (p<0.001). LBM at remission was directly correlated with increased DHA (r=0.487, p=0.034) and EPA (r=0.499, p=0.030) erythrocytes in the LCPUFA-ω3 group. At ALL diagnosis and during the first three months of treatment, 100mg/kg of body weight/d DHA and EPA decreased LBM loss and allowed the incorporation of fatty acids into cell membranes (clinicaltriasl.gov #: NCT01051154).